Full Generic Medicine Info
Dosage/Direction for Use

Adult: Mild to moderate: Initially, 75 mg daily as single or in divided doses for 2 wk, then gradually increase in 25 mg increments as required and tolerated. Max: 150 mg daily. Severely depressed, hospitalised patient: Initially, 100-150 mg daily, gradually increased as required and tolerated. Max: 225 mg daily.
Elderly: Initially, 25 mg daily. May increase gradually to 50-75 mg daily, according to response.
May be taken with or without food.
Seizure disorders. Concomitant use during or w/in 14 days of MAOI use.
Special Precautions
Patient w/ history of increased intraocular pressure, phaeochromocytoma, chronic severe constipation and urinary retention (e.g. prostatic disease), risk of QT prolongation, bipolar disorder (or risk of), CV disease (e.g MI), hyperthyroidism, nocturnal enuresis. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Concomitant electroconvulsive therapy. Avoid abrupt withdrawal. Patient Counselling This drug may cause blurred vision, dizziness and other CNS symptoms, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for symptoms of clinical worsening, unusual changes in behaviour and emergence of suicidality esp during initiation or dosage adjustment.
Adverse Reactions
Significant: Suicidality, clinical worsening, unusual behavioural changes, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, seizures, mild pupillary dilation. Rarely, hypomanic or manic episodes, neutrophil depression. Nervous: Drowsiness, dizziness, nervousness, headache, tremor. CV: Sinus tachycardia, palpitations, flushing, orthostatic hypotension. GI: Dry mouth, constipation, nausea, vomiting, abdominal disorders, increased appetite. Genitourinary: Erectile dysfunction, micturition disorder. Endocrine: Hot flush, abnormal wt gain. Musculoskeletal: Muscular weakness. Ophthalmologic: Blurred vision, accommodation disorder. Dermatologic: Rash, urticaria, photosensitivity, hyperhidrosis. Others: Fatigue, pyrexia.
Potentially Fatal: Rarely, ventricular tachycardia, ventricular fibrillation, torsade de pointes.
Symptoms: Somnolence, stupor, coma, ataxia, restlessness, agitation, enhanced reflexes, muscular rigidity and choreo-athetotic movements, convulsions, hypotension, tachycardia, QT prolongation, arrhythmias, conduction disorders, shock, heart failure, ventricular tachycardia, ventricular fibrillation, torsade de pointes, cardiac arrest, resp depression, cyanosis, vomiting, fever, mydriasis, sweating and oliguria or anuria. Management: Symptomatic and supportive treatment. Protect patient's airway. Establish an IV line and initiate GI decontamination including large volume gastric lavage followed by admin of activated charcoal.
Drug Interactions
May cause increased atropine-like effects w/ anticholinergic and sympathomimetic drugs. Phenothiazines and benzodiazepines (w/ rapidly tapered dose) may increase risk of seizures. Thyroid drugs may increase CV adverse effects. Increased plasma concentration w/ hepatic enzyme inhibitors (e.g. cimetidine, fluoxetine). Decreased plasma concentration w/ hepatic enzyme inducers (e.g. barbiturates, phenytoin). May increase effects of barbiturates and other CNS depressants. May decrease pharmacologic effects of antihypertensive drugs (e.g. guanethidine).
Potentially Fatal: Risk of severe interactions including hyperpyrexia, tremor, delirium, and generalised clonic convulsions w/ MAOIs.
Food Interaction
May increase CNS depressant effect of alcohol. Avoid alcohol.
Maprotiline, a tetracyclic antidepressant and non-selective monoamine reuptake inhibitor, also inhibits norepinephrine reuptake in the presynaptic neuronal membrane. It alleviates the mood, anxiety, agitation and psychomotor retardation.
Absorption: Slowly but completely absorbed from the GI tract. Absolute bioavailability: 66-70%. Time to peak plasma concentration: 8-24 hr.
Distribution: Widely distributed. Enters breast milk. Volume of distribution: 23-27 L/kg. Plasma protein binding: 88-90%.
Metabolism: Metabolised in the liver via demethylation mainly by CYP2D6 to desmethylmaprotiline; further metabolised via hydroxylation and conjugation.
Excretion: Via urine (70%) and faeces (30%). Elimination half-life: 51 hr.
Oral: Store between 20-25°C. Protect from light.
CIMS Class
ATC Classification
N06AA21 - maprotiline ; Belongs to the class of non-selective monoamine reuptake inhibitors. Used in the management of depression.
Disclaimer: This information is independently developed by CIMS based on maprotiline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in